Mammoth Biosciences
Mammoth Biosciences to Receive $100M Upfront in Therapeutic CRISPR Gene Editing Deal With Regeneron
Mammoth is also eligible to receive up to $370 million per target in development, as well as regulatory and commercial milestone payments and royalties from product sales.